Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) have earned a consensus recommendation of “Buy” from the twelve brokerages that are presently covering the firm. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $146.94.

Several equities research analysts recently commented on GWPH shares. Cantor Fitzgerald lifted their price objective on GW Pharmaceuticals PLC from $165.00 to $182.00 and gave the stock a “buy” rating in a report on Monday, September 26th. Cowen and Company reiterated a “buy” rating and issued a $135.00 price objective on shares of GW Pharmaceuticals PLC in a report on Tuesday, August 9th. Goldman Sachs Group Inc. started coverage on GW Pharmaceuticals PLC in a report on Friday, October 7th. They issued a “buy” rating and a $189.00 price objective for the company. Leerink Swann reiterated a “buy” rating and issued a $162.00 price objective on shares of GW Pharmaceuticals PLC in a report on Thursday, November 3rd. Finally, Vetr upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating and set a $91.16 price objective for the company in a report on Monday, August 8th.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in shares of GW Pharmaceuticals PLC by 18.6% in the first quarter. Renaissance Technologies LLC now owns 179,400 shares of the biopharmaceutical company’s stock worth $12,944,000 after buying an additional 28,100 shares during the period. Deerfield Management Co. boosted its position in GW Pharmaceuticals PLC by 117.5% in the first quarter. Deerfield Management Co. now owns 674,373 shares of the biopharmaceutical company’s stock worth $48,656,000 after buying an additional 364,251 shares in the last quarter. Seven Eight Capital LLC boosted its position in GW Pharmaceuticals PLC by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,300 shares in the last quarter. Rothschild Investment Corp IL acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $200,000. Finally, Profit Investment Management LLC acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $260,000. Institutional investors own 68.72% of the company’s stock.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 118.66 on Tuesday. The company’s market capitalization is $2.60 billion. GW Pharmaceuticals PLC has a 12 month low of $35.83 and a 12 month high of $137.88. The stock’s 50 day moving average price is $124.83 and its 200 day moving average price is $99.87.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.